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Abstract Distal tibial and fibular fractures, particularly in
patients with comorbidities, heal slowly and have a high
incidence of postoperative nonunion and infection. Autol-
ogous concentrated bone marrow aspirate (cBMA) and
platelet-rich plasma (PRP) increase osteogenic potential of
demineralized bone matrix (DBM). The purpose of this
case series was to evaluate the efficacy of cBMA, PRP,
DBM in conjunction with the Ilizarov fixator as compared
to DBM and the Ilizarov fixator alone in expediting frac-
ture healing. Ten patients (mean age 52.9 years) were in
the cBMA Group, and 10 patients (mean age 54 years)
were in the Control Group. Comorbidities included dia-
betes, obesity, smoking, and renal disease. Radiographs
showed a significant difference in the rate of complete
healing in the cBMA Group at 16 ± 1.6 weeks post-sur-
gery as compared to 24 ± 1.3 weeks in the Control Group
(P\ 0.001). No differences were observed between groups
in infection rate or nonunions. We conclude that the Ili-
zarov fixator combined with DBM, cBMA, and PRP
expedites fracture healing of the distal tibia and fibula in
patients with significant comorbidities.
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Introduction
Distal tibial and fibula fractures can be treated success-
fully with the Ilizarov fixator [1]. However, complica-
tions include contractures, pin track infections, loss of
range of motion, and articular damage. Patients who are
experiencing soft-tissue loss, comorbidities, and chronic
infection increase the complexity of these cases. Patients
who are smokers and of advanced age with a high rate
of systemic illness are the most difficult to treat because
these factors negatively impact the rate of healing and
incidence of infection [2, 3]. The challenge surgeons
face with these patients is to achieve a stable, well-
aligned, mobile and pain-free joint while minimizing the
risk of infection and post-traumatic osteoarthritis. The
classic Ilizarov technique has several advantages when
treating patients with various comorbidities [4]. With this
technique, the reduction and fixation of the fracture is
performed with minimal soft-tissue exposure and blood
loss and the fixation stable enough to allow weight-
bearing soon after surgery. The external fixator gives the
surgeon the opportunity to adjust the alignment and
compress or distract during or after surgery. These fac-
tors improve the success rate of the Ilizarov method in
fracture repair and contribute a positive effect on patient
quality of life [5].
In the treatment for complicated fractures, surgeons may
use autologous iliac bone graft (ICBG) to augment healing.
Unfortunately, in patients with multiple comorbidities,
autologous bone grafting may introduce new complica-
tions. These include bleeding, infection, and chronic pain
at the donor site. There can be limited bone graft material
available for treatment [6]. Since the success of a bone
graft is determined by the ability of the grafted tissue to
recruit progenitor cells to the injured area to form
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osteoblasts for healing, alternative methods are needed in
compromised patients.
Safe and effective alternative graft materials have
become popular for use in patients with significant
comorbidities. Demineralized bone matrix (DBM) is donor
tissue that has been processed to remove inorganic mineral
content resulting in an organic collagen matrix [7]. This
leaves DBM with minimal osteoinductive properties.
Additional material which improves the osteogenic envi-
ronment can be obtained from bone marrow aspirate which
is concentrated for osteoprogenitor cells. The benefit of
bone marrow separation is twofold: Red blood cells are
removed since they can interfere with bone formation and
healing [6], and concentrated osteoprogenitor cells increase
the osteogenic stimulus. This use of concentrated bone
marrow aspirate (cBMA) combined with an osteoinductive
bone graft substitute (DBM) insures that two of the main
properties for bone growth and healing, osteogenesis and
osteoinduction, are present with minimal risk and mor-
bidity to the patient. Concentrated BMA provides osteo-
genic mesenchymal stem cells (MSCs) and hematopoietic
stem cells (HSCs). Mesenchymal stem cells secrete various
bioactive factors, have inherent differentiation potential,
and modulate angiogenic and growth factors in the local
microenvironment [8–10]. In addition, MSCs exert anti-
inflammatory and immunosuppressive signaling which
protect against tissue destruction while facilitating regen-
eration. Pluripotent hematopoietic stem cells (HSCs)
derived from autologous bone marrow may also provide
pro- and anti-inflammatory signaling while stimulating the
production of angiogenic growth factors via paracrine
effects in the treated area [11]. Together, cBMA combined
with DBM may expedite healing rates.
The use of platelet-rich plasma (PRP) can augment the
healing process of soft tissues following surgical inter-
ventions. PRP is a biological intervention prepared as a
platelet concentrate after centrifugation of the patient’s
whole blood. Through centrifugation, the majority of the
red blood cell components and the plasma volume are
removed resulting in a post-processed concentration of
therapeutic factors (i.e., platelets and white blood cells).
Production of PRP also concentrates endogenous growth
factors in circulating blood. These factors include platelet-
derived growth factor (PDGF), vascular endothelial growth
factor (VEGF), transforming growth factor-beta (TGF-b1),
epidermal-derived growth factor (EGF), and fibroblast
growth factor (FGF) [12–15]. Collectively, PRP stimulates
hemostasis, reduces infection, and enhances skin regener-
ation [16].
The aim of this retrospective case series was to compare
the outcome of cBMA and PRP in expediting healing of
distal tibial and fibula fractures when used with DBM and




Twenty patients (n = 20) were included in this retrospec-
tive study. Ten patients (n = 10, mean age 52.9 years)
were in the cBMA Group, and 10 patients (n = 10, mean
age 54 years) were in the Control Group. Comorbidities
included diabetes, obesity, smoking, and renal disease. Ten
patients in the cBMA Group had abnormal bone metabo-
lism indicated by vitamin D and calcium deficiency as to
seven patients in the Control Group. All patients had closed
distal tibial and fibula fractures with a poor soft-tissue
envelope.
The study protocol, medical record review procedures,
and data analysis were approved by the PresenceSM Saint
Joseph Hospital Institutional Review Board. Patients were
treated between January 2010 and December 2012 with a
mean follow-up time of 18 months. Patients were identified
by a retrospective review of the electronic medical records.
The two cohorts (treatment and control) were identified
through the case note review. All identifying data (name,
DOB (only age included), demographics) were removed
from electronic medical records prior to data analysis.
Intervention
Bone marrow aspiration and concentration
For the 10 patients in the cBMA Group, 26 ml of bone
marrow was harvested from the medial aspect of the
proximal tibia (Fig. 1a). First, the 30-ml syringe was
primed with 4 ml of anticoagulant citrate dextrose solution
(ACD-A) (Arteriocyte Medical Systems, Hopkinton, MA).
A mallet was then used to advance the 15-gauge Jamshidi
needle (Arteriocyte Medical Systems, Hopkinton, MA)
until a decrease in resistance was met. The decreased
resistance was used to indicate that the needle had entered
the marrow cavity. Bone marrow was then drawn back
gently (to prevent lysing of the cells) into the 30-ml syringe
that was primed with 4 ml of ACD-A. During the marrow
draw, if significant resistance was met, the needle was
repositioned until the marrow flowed easily. This prevented
clotting and unnecessary physical disruption of the aspirate
and avoid cell lysis and a reduction in growth factor con-
tent of the platelets. The needle was repositioned until a
total volume of 30 ml, including the ACD-A, was
harvested.
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The harvested marrow was then filtered and processed in
the Arteriocyte Magellan system (Arteriocyte Medical
Systems, Inc., Hopkinton, MA) (Fig. 1b). The Magellan
is an automatic, dual spin, closed system allowing for safe
and rapid bedside concentration of whole blood and bone
marrow aspirate. For each case, the Magellan was cus-
tomized to obtain a final volume of cBMA of approxi-
mately 3 ml from 30 ml of bone marrow aspirate.
Phlebotomy and concentration of PRP
For each patient in the cBMA Group, 30 ml of whole blood
was drawn from an antecubital vein. The 30-ml syringe
was primed with 4 ml of ACD-A before 26 ml of whole
blood was obtained from each patient using standard
phlebotomy procedures. On reaching the final volume of
30 ml, the syringe was loaded into the Magellan System.
The Magellan was programmed to produce 3 ml of PRP
from the 30 ml volume (Fig. 1b).
DBM
Integra Accell EVO, which is a DBM and poloxamer
Reverse-Phase Medium produced by Integra (Irvine, CA),
was used in all patients (cBMA Group and Control Group).
This form of DBM provides a high surface area which
Fig. 1 Tissue harvesting and application. a Bone marrow aspiration
method. b Magellan platelet separator. c Syringe containing initial
mixture of cBMA and DBM. d Final implantable mixture of cBMA
and DBM. e Application of cBMA and graft material to fracture site.
f Application of PRP using a spray tip cannula
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facilitates binding access for natural bone proteins and a
scaffold and signal for new bone formation. The Accell
EVO DBM is moldable putty at room temperature which
becomes more viscous at body temperature.
Prior to use, the Accell EVO DBM was mixed with the
cBMA (cBMA Group only) to achieve desired consistency
(Fig. 1c, d). Five cc. of the Accell EVO DBM was injected
into fracture sites in both groups (Fig. 1e).
Ilizarov technique
The circular fixator consisted of a pre-constructed frame
that consisted of four rings (Fig. 2). A proximal reference
wire was fixed and tensioned to the most proximal ring. A
distal reference wire was fixed directly proximal to the
ankle. After the bone ends were fixed with opposing olive
wires, radiology was used to ascertain alignment of the
bone. In cases where the fracture was close to the ankle, the
foot was incorporated into the frame to enhance stability
and prevent equinus or varus contracture. With the bones
were aligned, the cBMA (cBMA Group only) and Accell
EVO DBM mixture (cBMA and Control Groups) were
injected percutaneously using the 15-gauge bone marrow
aspiration needle (Fig. 1e). Viability of the foot was
assessed via palpation of the dorsalis pedis and posterior
tibial pulses and measurement of oxygen saturation of the
hallux. If circulation appeared to be disrupted, the length
was adjusted as necessary to return circulation to normal.
PRP combined with calcium chloride and thrombin solu-
tion was applied using a spray tip cannula at all surgical
wound sites in the cBMA Group (Fig. 1f).
Patients were assessed every 2 weeks via X-ray to
determine whether the fracture was completely healed and
whether frame removal was appropriate. A single observer
evaluated the X-rays to determine whether cortices were
fully ossified, determined by a sharp outline of the cortical
bone. In addition, each patient needed to be able to bear
weight on the limb for the frame to be removed. If patients
were not healed by week 12, a CT scan was performed.
Patients then returned every 2–4 weeks for X-ray or CT
scan, respectively, until complete healing was determined.
Once the frame was removed, patients were fitted with a
patellar tendon brace and instructed to wear the brace for
6 months after frame removal.
Data collection and statistical analysis
A sample size estimation was performed to identify the
number of subjects needed to detect a significant difference
in rate of healing between treatment conditions (control vs.
cBMA). Sample size estimate ranges were generated using
effect sizes and standard deviations at a power of 0.8 and
alpha of 0.05 (SigmaPlot v 10.0, Systat Software Inc.,
Germany). The outcome measures were assessed by
physical examination, radiographic examination, and
chart review. The mean ± standard deviation was calcu-
lated for all measurements reported. To describe the out-
comes of the surgical intervention, frequencies and
percentages were used for the categorical variables. A one-
way analysis of variance (ANOVA) between groups was
performed to determine whether there was a significant
difference between the rate of healing in the cBMA Group
and the Control Group. The critical alpha level was set at
0.05.
Results
Figure 3 illustrates outcome measures for the cBMA and
Control Groups. The mean fixator time was
24 ± 1.3 weeks in the Control Group and 16 ± 1.6 weeks
in the cBMA Group (P\ 0.001). In the Control Group,
postoperative radiographs for seven of 10 patients showed
complete bone healing at the time of external fixator
removal. In the cBMA Group, eight of 10 patients showed
complete bone healing when the external fixator was
removed at approximately 16 weeks post-surgery (Fig. 4).
There were no significant differences between groups in
the number of patients with complete bone healing
(P = 0.6) at the time of fixator removal. Of the two
patients in the cBMA Group who experienced delayed
union, only one revision was required due to consistent
pain. Four weeks post-revision, the patients’ pain had
subsided. The second patient did not require a revision, but
a percutaneous injection of cBMA was used to augment
healing. Both patients healed within approximately
Fig. 2 Ilizarov method of fixation. The circular fixator consisted of a
pre-constructed frame that consisted of four rings. A proximal
reference wire was fixed and tensioned to the most proximal ring. A
distal reference wire was fixed directly proximal to the ankle
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4 months without residual deformity or morbidity. In the
Control Group, three patients developed a stiff nonunion
without deformity. These patients were braced and were
followed for 18 months until complete healing was
observed. No surgical revisions were necessary.
Two patients in the cBMAGroup experienced superficial
irritation as a result of the wires. Antibiotics were not needed
in these patients. In the Control Group, two patients devel-
oped an infection that required treatment with oral antibi-
otics. The incidence of infection was not different between
groups (P = 0.2). No limbs were amputated in this series.
Discussion
The aim of the author’s strategy in combining cBMA and
PRP with the Ilizarov technique and DBM was to decrease
the period of external fixation, expedite fracture healing,
and diminish the rate of complications, specifically infec-
tions. In agreement with our hypothesis, patients treated
with cBMA and PRP healed significantly faster than
patients in the Control Group. Complications experienced
by patients in the cBMA Group were minor, and only one
required additional surgery. In the Control Group, three
patients experienced nonunion complications, and two
experienced skin infections requiring treatment with oral
antibiotics. These were not statistically significant, but the
trend of fewer skin infections may have arisen from use of
PRP at the incision sites in the cBMA Group [17]. Previous
reports have evaluated the potent antimicrobial effects of
PRP and suggested the combined actions of concentrated
levels of leukocytes, platelets, and their derived growth
factors have strong bacterial inhibitory effects.
Nonunion is a major challenge to surgeons when treat-
ing complex fractures in a patient with multiple comor-
bidities. Open bone grafting techniques for the treatment
for complex fractures have remained unchanged since the
early work of Phemister and colleagues [18]. Complica-
tions of this technique range from infection, hematoma,
and to donor site morbidity. As bone growth is optimal
when osteogenic cells are present, techniques that induce
osteogenesis while not inducing donor site morbidity in an
already-compromised patient are still needed.
This retrospective cohort comparison highlights the
benefits of using an autologous source of cells derived
from a patient’s bone marrow aspirate to provide an
osteogenic milieu. Specifically, mesenchymal cells con-
centrated from the patient’s bone marrow are multipotent
and are able to differentiate into osteoprogenitor cells
and osteocytes [19]. Both groups of cells have critical
roles in bone remodeling. It is suggested that when
osteogenic cells were combined with the inductive
properties of the DBM and the stable environment of
Ilizarov fixation in this series, healing outcomes were
improved and time to union reduced as compared to the
Control Group without osteoprogenitor cells. This strat-
egy is of importance in this patient sample as patients
here had multiple comorbidities that are associated with
poor fracture healing.
There are few reports in the literature evaluating the
efficacy of cBMA in conjunction with DBM to promote
fracture healing. To our knowledge, this is the first cohort
comparison to evaluate the combined use of PRP, cBMA,
DBM, and the Ilizarov method in patients with various
comorbidities; there was a significant reduction in external
fixator time and time to healing. Several reports in the
literature suggest the use of PRP on chronic wounds or at
postoperative incisions promotes antimicrobial activity,
and reduces infection [20]. There was a trend suggested
here as no patients in the cBMA Group required oral



















Fig. 3 Postoperative outcome measures. There was a significant
reduction in the time of external fixation in the cBMA Group. No
differences were reported in incidence of infection or nonunion
between groups. Data are mean ± SD. *P\ 0.001
Fig. 4 Serial radiographs. a Pre-treatment radiograph of a female
patient in the cBMA Group with a bimalleolar fracture (yellow arrow).
B Fluoroscopy image of olive wire stabilization of the fracture. c Post-
treatment radiographs of same female patient at 16 weeks post-
procedure. Fracture is healed (yellow arrow) (color figure online)
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The limitations of this study include the retrospective
nature, the limited number of patients, and the time points at
which data were collected. Another factor, currently under
investigation in our research group, is the potential vari-
ability in the number of progenitor cells (MSCs andHSCs) in
a sample of cBMA from each patient. In the population
studied, the presence of multiple comorbidities introduces
the possibility that patients in the cBMAGroupwith delayed
healing had suboptimal numbers of progenitor cells in their
cBMA sample; a larger sample size will be required as well
as prior progenitor cell analysis so that patients can be ran-
domized according to progenitor cell number.
In conclusion, the use of DBM saturated with cBMA in
combination with the Ilizarov technique results in an 85 %
healing rate in approximately 4 months. We conclude this
strategy is safe, reliable, and effective with good clinical
outcomes for the treatment for complex fractures in
patients with significant comorbidities.
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